The Stock the Market Has Been Too Quick to Dismiss

Eli Lilly (LLY) has shed roughly 15% from its all-time high of approximately $1,134 set in late November 2025. As of early May 2026, shares trade near $963 – a level that has begun attracting institutional attention despite persistent concerns about GLP-1 competitive dynamics and near-term pricing pressure.

The pullback reflects genuine uncertainty. Novo Nordisk’s oral semaglutide franchise (which launched in January 2026 as the first oral GLP-1 pill for obesity), Roche’s emerging oral GLP-1 program, and a growing list of biosimilar candidates have introduced competitive noise that was largely absent eighteen months ago. But the bear case has materially overshot, and the fundamental picture for Lilly heading into its next earnings report – scheduled for August 5, 2026 – tells a more nuanced story.

Company Profile: More Than a GLP-1 Trade

Eli Lilly is the most valuable pharmaceutical company in the world by market capitalization, with a 2025 revenue base of approximately $65.2 billion – a 45% increase over 2024. While tirzepatide – marketed as Mounjaro for type 2 diabetes and Zepbound for obesity – has dominated investor attention, Lilly operates meaningful franchises across oncology, immunology, and neuroscience.

• Mounjaro and Zepbound combined generated approximately $12.8 billion in Q1 2026 alone, with full-year 2025 tirzepatide revenue significantly exceeding $30 billion across all four quarters
• Verzenio (abemaciclib) for breast cancer delivered approximately $5.7 billion in annual revenue in 2025
• Kisunla, the company’s Alzheimer’s treatment approved in mid-2024, is ramping through early commercial stages and became the U.S. market leader in amyloid-targeting therapy
• Jaypirca (pirtobrutinib) for certain leukemia subtypes adds oncology diversification, with global sales growing 79% year-over-year in Q1 2026

The pipeline depth is what separates Lilly from a single-asset story. The company had 36 active Phase 3 programs as of Q1 2026. Orforglipron – an oral GLP-1 receptor agonist with no food or water timing restrictions – was submitted to the FDA for approval in late 2025 and launched in the U.S. in early 2026 under the brand name Foundayo, with more than 20,000 patients starting the drug in its first few weeks on market.

The Supply and Pricing Debate

Throughout 2024 and into 2025, Lilly faced meaningful manufacturing constraints that limited Zepbound availability and capped near-term revenue upside. The FDA declared the tirzepatide shortage over, and Lilly has committed more than $27 billion in new domestic manufacturing investment – on top of $23 billion committed since 2020 – bringing its total U.S. manufacturing commitment to over $50 billion. Facilities in Indiana, North Carolina, Wisconsin, Virginia, Texas, and Pennsylvania are part of this buildout.

What’s replacing the supply constraint conversation is a pricing conversation. Q1 2026 revenue grew 56% year-over-year to $19.8 billion, but management guided for price to be a drag in the low-to-mid teens for full-year 2026 as PBM negotiations, the government obesity access agreement, and Medicaid pricing all weigh on realized prices. Volume growth is expected to more than offset this – and so far it has – but the margin of error is narrower than it was a year ago.

Analyst Targets and Positioning

• Morgan Stanley – Overweight, $1,344 price target
• JPMorgan – Overweight, $1,300 price target
• Cantor Fitzgerald – Overweight, $1,230 price target
• Barclays – Overweight, $1,350 price target
• Jefferies – Buy, $1,300 price target

The consensus 12-month price target sits near $1,220, implying approximately 27% upside from current levels. That gap between current price and consensus target reflects a market that has repriced the stock lower on competitive fears, even as underlying fundamentals – Q1 2026 beat estimates by over $2 billion on revenue and $1.58 on EPS – remain intact.

What Investors Should Watch Through Mid-2026

• Foundayo (orforglipron) prescription ramp – early weeks showed 20,000+ patients, but trajectory vs. Novo’s oral Wegovy rollout is the key competitive read
• Medicare GLP-1 Bridge access beginning July 1, 2026 – eligible Part D beneficiaries at $50/month, a potential step-function demand unlock not yet in prescription numbers
• International launch pace for Zepbound, particularly in markets where Mounjaro is already reimbursed
• FDA action on compounded tirzepatide – the FDA has proposed excluding tirzepatide’s active ingredient from the bulk compounding list, which would be a direct volume catalyst for branded Zepbound
• Q2 2026 earnings on August 5, 2026 – watch Mounjaro and Zepbound combined net revenue against full-year guidance of $82–85 billion

Bull, Base, and Bear

Bull case: Foundayo prescription ramp accelerates, Medicare access drives a step-change in volume, and compounded alternatives face formal regulatory action. Lilly re-tests prior highs near $1,100 to $1,134 by year-end 2026.

Base case: Execution remains steady, pricing headwinds are absorbed by volume growth, and guidance is maintained or modestly raised. Stock recovers toward $1,050 to $1,100 as sentiment normalizes.

Bear case: Oral GLP-1 competition from Novo Nordisk’s Wegovy pill or Viking Therapeutics accelerates faster than anticipated, Foundayo disappoints on uptake, or a pricing concession larger than modeled hits margins. Stock revisits the low $800s.

Bottom Line

Eli Lilly at $963 is a fundamentally different risk-reward than Eli Lilly at $1,134. The core franchise is intact – $19.8 billion in Q1 revenue, guidance raised to $82–85 billion for full-year 2026, and a pipeline that now includes a launched oral GLP-1. The pullback has been driven more by competitive fear and pricing anxiety than by a deterioration in the underlying business. For investors with a 12- to 18-month horizon, the current entry point warrants serious consideration.

For informational purposes only.